Unknown

Dataset Information

0

Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer.


ABSTRACT: Inflammatory breast cancer (IBC) is the most lethal and least understood form of advanced breast cancer. Its lethality originates from its nature of invading the lymphatic system and absence of a palpable tumor mass. Different from other metastatic breast cancer cells, IBC cells invade by forming tumor spheroids that retain E-cadherin-based cell-cell adhesions. Herein we describe the potential of the medicinal mushroom Ganoderma lucidum (Reishi) as an attractive candidate for anti-IBC therapy. Reishi contains biological compounds that are cytotoxic against cancer cells. We report the effects of Reishi on viability, apoptosis, invasion, and its mechanism of action in IBC cells (SUM-149). Results show that Reishi selectively inhibits cancer cell viability although it does not affect the viability of noncancerous mammary epithelial cells. Apoptosis induction is consistent with decreased cell viability. Reishi inhibits cell invasion and disrupts the cell spheroids that are characteristic of the IBC invasive pathology. Reishi decreases the expression of genes involved in cancer cell survival and proliferation (BCL-2, TERT, PDGFB), and invasion and metastasis (MMP-9), whereas it increases the expression of IL8. Reishi reduces BCL-2, BCL-XL, E-cadherin, eIF4G, p120-catenin, and c-Myc protein expression and gelatinase activity. These findings suggest that Reishi is an effective anti-IBC therapeutic.

SUBMITTER: Martinez-Montemayor MM 

PROVIDER: S-EPMC3201987 | BioStudies | 2011-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3585368 | BioStudies
1000-01-01 | S-EPMC5432221 | BioStudies
2013-01-01 | S-EPMC6135947 | BioStudies
2019-01-01 | S-EPMC6710038 | BioStudies
2021-01-01 | S-EPMC7811004 | BioStudies
2010-01-01 | S-EPMC2922340 | BioStudies
2017-01-01 | S-EPMC5556652 | BioStudies
2015-01-01 | S-EPMC4514595 | BioStudies
2017-01-01 | S-EPMC5559319 | BioStudies
1000-01-01 | S-EPMC3326557 | BioStudies